Abstract
Background/Aims: We have previously demonstrated that a transcription factor, upstream stimulatory factor 2 (USF2), regulates glucose-induced thrombospondin 1 expression and transforming growth factor-β activity in mesangial cells, and plays an important role in diabetic glomerulopathy. In this study, we determined whether USF2 expression in renal proximal tubular cells is regulated by glucose and contributes to diabetic tubulointerstitial fibrosis. Methods: Human renal proximal tubular cells (HK-2 cells) were treated with normal- or high-glucose medium for 24 h. After treatment, real-time PCR or immunoblotting was used to determine the expression of USF2 and other components of the renin-angiotensin system in HK-2 cells. Results: High glucose upregulated USF2 expression and increased extracellular matrix accumulation in HK-2 cells; both were inhibited by siRNA-mediated USF2 knockdown. In addition, high glucose stimulated angiotensinogen and renin expression, increased renin activity, and resulted in increased angiotensin II formation. Treatment of HK-2 cells with an angiotensin II receptor 1 (AT1) blocker – losartan – prevented high-glucose-induced USF2 expression and high-glucose-enhanced phosphorylation of CREB (cAMP response element-binding protein). Conclusion: Our data established that high glucose stimulated USF2 expression in HK-2 cells, at least in part, through angiotensin II-AT1-dependent activation of CREB, which can contribute to diabetic tubulointerstitial fibrosis.
References
1.
Ishimura E, Sterzel RB, Morii H, Kashgarian M: Extracellular matrix protein: gene expression and synthesis in cultured rat mesangial cells. Nippon Jinzo Gakkai Shi 1992;34:9–17.
[PubMed]
2.
Gurley SB, Coffman TM: The renin-angiotensin system and diabetic nephropathy. Semin Nephrol 2007;27:144–152.
[PubMed]
3.
Carey RM, Siragy HM: The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003;14:274–281.
[PubMed]
4.
Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G: Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;19:19.
[PubMed]
5.
Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE: Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007;8:8.
[PubMed]
6.
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–2446.
[PubMed]
7.
Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ: Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor-β1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. J Renin Angiotensin Aldosterone Syst 2004;5:146–151.
[PubMed]
8.
Singh R, Alavi N, Singh AK, Leehey DJ: Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999;48:2066–2073.
[PubMed]
9.
Price DA, Porter LE, Gordon M, Fisher ND, De’Oliveira JM, Laffel LM, Passan DR, Williams GH, Hollenberg NK: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10:2382–2391.
[PubMed]
10.
Burden AC, Thurston H: Plasma renin activity in diabetes mellitus. Clin Sci (Lond) 1979;56:255–259.
[PubMed]
11.
Leehey DJ, Singh AK, Bast JP, Sethupathi P, Singh R: Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl Res 2008;151:208–216.
[PubMed]
12.
Singh R, Singh AK, Leehey DJ: A novel mechanism for angiotensin ii formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 2005;288:F1183–1190.
[PubMed]
13.
Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993;265:F477–F486.
[PubMed]
14.
Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Chan JS: Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor-β1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. J Am Soc Nephrol 2002;13:302–312.
[PubMed]
15.
Sawadogo M, Roeder RG: Interaction of a gene-specific transcription factor with the adenovirus major late promoter upstream of the TATA box region. Cell 1985;43:165–175.
[PubMed]
16.
Sirito M, Lin Q, Maity T, Sawadogo M: Ubiquitous expression of the 43- and 44-kDa forms of transcription factor USF in mammalian cells. Nucleic Acids Res 1994;22:427–433.
[PubMed]
17.
Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE: Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-β activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem 2004;279:34311–34322.
[PubMed]
18.
Shi L, Liu S, Nikolic D, Wang S: High glucose levels upregulate upstream stimulatory factor 2 gene transcription in mesangial cells. J Cell Biochem 2008;103:1952–1961.
[PubMed]
19.
Liu S, Shi L, Wang S: Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury. Am J Physiol Renal Physiol 2007;293:F1727–F1735.
[PubMed]
20.
McMurray HR, McCance DJ: Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J Virol 2003;77:9852–9861.
[PubMed]
21.
Shi L, Nikolic D, Liu S, Lu H, Wang S: Activation of renal renin-angiotensin system in upstream stimulatory factor 2 transgenic mice. Am J Physiol Renal Physiol 2009;296:F257–F265.
[PubMed]
22.
Wang S, Wu X, Lincoln TM, Murphy-Ullrich JE: Expression of constitutively active cGMP-dependent protein kinase prevents glucose stimulation of thrombospondin 1 expression and TGF-β activity. Diabetes 2003;52:2144–2150.
[PubMed]
23.
Singh R, Singh AK, Alavi N, Leehey DJ: Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003;14:873–880.
[PubMed]
24.
Hsieh TJ, Fustier P, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Fantus IG, Hamet P, Chan JS: High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003;144:4338–4349.
[PubMed]
25.
Feliers D, Kasinath BS: Mechanism of VEGF expression by high glucose in proximal tubule epithelial cells. Mol Cell Endocrinol 2009;314:136–142.
[PubMed]
26.
Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Carriere S, Chan JS: Effect of renin-angiotensin system blockade on the expression of the angiotensinogen gene and induction of hypertrophy in rat kidney proximal tubular cells. Exp Nephrol 2001;9:109–117.
[PubMed]
27.
Satou R, Gonzalez-Villalobos RA, Miyata K, Ohashi N, Katsurada A, Navar LG, Kobori H: Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells. Am J Physiol Renal Physiol 2008;295:F283–F289.
[PubMed]
28.
Cui XL, Ding Y, Alexander LD, Bao C, Al-Khalili OK, Simonson M, Eaton DC, Douglas JG: Oxidative signaling in renal epithelium: critical role of cytosolic phospholipase A2 and p38(SAPK). Free Radic Biol Med 2006;41:213–221.
[PubMed]
29.
Porter AG, Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999;6:99–104.
[PubMed]
30.
Villegas G, Lange-Sperandio B, Tufro A: Autocrine and paracrine functions of vascular endothelial growth factor (VEGF) in renal tubular epithelial cells. Kidney Int 2005;67:449–457.
[PubMed]
31.
Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, Shim H: CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007;359:716–722.
[PubMed]
32.
Iqbal M, Okazaki Y, Okada S: In vitro curcumin modulates ferric nitrilotriacetate (Fe-NTA) and hydrogen peroxide (H2O2)-induced peroxidation of microsomal membrane lipids and DNA damage. Teratog Carcinog Mutagen 2003;suppl 1:151–160.
33.
Diaz-Meco MT, Moscat J: Akt regulation and lung cancer: a novel role and mechanism of action for the tumor suppressor Par-4. Cell Cycle 2008;7:2817–2820.
[PubMed]
34.
Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran A, Pathrose P, Leitges M, Cañamero M, Collado M, Salas C, Serrano M, Moscat J, Diaz-Meco MT: Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J 2008;27:2181–2193.
[PubMed]
35.
Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran A, Pathrose P, Leitges M, Cañamero M, Collado M, Salas C, Serrano M, Moscat J, Diaz-Meco MT: Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J 2008;27:2181–2193.
[PubMed]
© 2010 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2010
You do not currently have access to this content.
